drugset
drugset / Trial / NCT04930003

Reactogenicity, Safety and Immunogenicity of QazCoVac-P COVID-19 Vaccine

NCT04930003 ↗

Phase 1/2 Completed 244 enrolled Research Institute for Biological Safety Problems
RandomizedParallel-groupSingle-blindPrevention

Summary

Randomized, Blind, Placebo-controlled Phase- I Study and Randomized, Open Phase Phase-II Study of QazCoVac-P - COVID-19 Subunit Vaccine in Healthy Adult Volunteers From 18 Years Old and Elder

Timeline

Start
2021-06-15
Primary completion
2021-12-15
Completion
2021-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject QazCoVac-P Vaccine 0.5 ml Intramuscular

Indications

COVID-19